Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ribavirin ANDAs Still Waiting For FDA; Other Generic Issues Have Priority

Executive Summary

FDA's final decision on the approvability of ANDAs for ribavirin is taking longer than expected while the agency resolves other complex generic drug issues

You may also be interested in...



HDMA Interim Head Is COO Hanagan; CEO Streck Retiring Dec. 31

The Healthcare Distribution Management Association has named Chief Operating Officer Nancy Hanagan to serve as interim CEO while the association searches for a successor to Ron Streck

Ribavirin ANDAs Await ICN Petition; FDA Generic Rule Takes Effect

The delay in approval for generic versions of Schering-Plough's Rebetol (ribavirin) illustrates one limitation of FDA's revised Waxman/Hatch regulations

CollaGenex Periostat Lawsuit Hinges On FDA “Antibiotic” Determination

A federal judge must determine whether CollaGenex' Periostat is properly classified as an "antibiotic" after preliminarily enjoining FDA from approving generic versions of doxycycline hyclate 20 mg

Related Content

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel